WA
ANIK icon

Winfield Associates’s Anika Therapeutics ANIK Stock Holding History

Winfield Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-87
Closed -$4K – 788
2017
Q2 		$4K Buy
+87
New +$4.01K ﹤0.01% 549

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Winfield Associates's ANIK Position: Q3 2017 in Review

Winfield Associates sold out of Anika Therapeutics (ANIK) in Q3 2017, closing a stake of 87 shares — an estimated $4K sold.

Winfield Associates first reported a position in ANIK in Q2 2017 and held it in 1 quarter. The position peaked at $4K in Q2 2017. 166 funds tracked by Wall St. Rank hold ANIK as of Q3 2017.

  • Winfield Associates reported no remaining Anika Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Winfield Associates sold 87 Anika Therapeutics shares in Q3 2017, an estimated $4K.
  • Winfield Associates first reported a position in Anika Therapeutics in Q2 2017 and held it in 1 quarter.
  • Winfield Associates's Anika Therapeutics position peaked at $4K in Q2 2017.
  • 166 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2017.

Based on Winfield Associates's 13F filing for Q3 2017, filed 6 Nov 2017.